がん診断の世界市場-2025年から2030年までの予測

がん診断市場は、CAGR 6.77％で2025年の1,317億3,300万米ドルから2030年には1,827億8,500万米ドルに成長すると予測されます。

がん診断市場は、画像検査（X線、CTスキャン、MRIなど）、血液検査、生検、遺伝子検査や腫瘍マーカー検査などの分子診断など、がんの発見に不可欠なツールや技術の開発、生産、商業化を包含します。早期かつ正確な診断は、タイムリーな治療を可能にすることで患者の予後を大幅に改善するため、この市場はヘルスケア産業にとって不可欠です。同市場は、がん罹患率の上昇と技術の進歩に牽引され、2025年から2030年にかけて力強い成長を遂げると予測されています。しかし、発展途上地域における高コストやアクセス制限などの課題が、市場拡大の妨げになる可能性があります。

市場促進要因

がん診断市場の主な促進要因は、世界のがん罹患率の上昇であり、これにより効果的な診断ツールの需要が高まっています。がん、特に乳がんの負担増は、治療成功率を高めるための早期発見の必要性を強調しています。政府の支援も重要な要因の一つであり、革新的な診断薬に対する規制当局の迅速な承認などのイニシアチブが市場の成長を後押ししています。例えば、早期発見と患者の転帰を改善するリキッドバイオプシーなどの高度診断技術の可能性を、規制当局が認識するようになってきています。さらに、業界各社による研究開発への投資拡大が診断ソリューションのイノベーションを促進し、市場をさらに押し上げています。

市場抑制要因

がん診断市場は、先進的な診断技術のコストが高く、特にリソースの乏しい環境ではアクセシビリティが制限されるなどの課題に直面しています。さらに、地域間のヘルスケアインフラの格差が、高度な診断法の普及を妨げています。新興諸国ではスクリーニングプログラムに対する認識やアクセスが限られていることも障壁となっており、診断が遅れ、市場成長に影響を与える可能性があります。費用対効果の高いソリューションと医療アクセスの拡大を通じてこれらの課題に対処することが、市場の持続的拡大には不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 市場スナップショット

• 市場概要
• 市場の定義
• 調査範囲
• 市場セグメンテーション

第3章 ビジネス情勢

• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析
• 業界バリューチェーン分析
• ポリシーと規制
• 戦略的提言

第4章 技術展望

第5章 がん診断の世界市場：診断手順別

• イントロダクション
• 臨床検査
• 画像検査手順
• ビプシー

第6章 がん診断の世界市場：がんタイプ別

• イントロダクション
• 肺がん
• 乳がん
• 大腸がん
• 皮膚がん
• 胃がん
• その他

第7章 がん診断の世界市場：エンドユーザー別

• イントロダクション
• 病院
• クリニック
• 診断センター

第8章 がん診断の世界市場：地域別

• イントロダクション
• 北米
  • 診断手順別
  • がんタイプ別
  • エンドユーザー別
  • 国別
    • 米国
    • カナダ
    • メキシコ
• 南米
  • 診断手順別
  • がんタイプ別
  • エンドユーザー別
  • 国別
    • ブラジル
    • アルゼンチン
    • その他
• 欧州
  • 診断手順別
  • がんタイプ別
  • エンドユーザー別
  • 国別
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • その他
• 中東・アフリカ
  • 診断手順別
  • がんタイプ別
  • エンドユーザー別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • その他
• アジア太平洋
  • 診断手順別
  • がんタイプ別
  • エンドユーザー別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • インドネシア
    • タイ
    • 台湾
    • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 市場シェア分析
• 合併、買収、合意およびコラボレーション
• 競合ダッシュボード

第10章 企業プロファイル

• bioMerieux SA
• Roche Diagnostics
• MetaCell
• Breath Diagnostics, Inc
• Metabiomics
• Castle Biosciences, Inc.
• Exact Sciences Corporation
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• GE Healthcare
• Siemens Healthineers（Siemens AG）

第11章 付録

• 通貨
• 前提条件
• 基準年と予測年のタイムライン
• 利害関係者にとっての主なメリット
• 調査手法
• 略語

The global cancer diagnostics market is expected to grow from USD131.733 billion in 2025 to USD182.785 billion in 2030, at a CAGR of 6.77%.

The cancer diagnostics market encompasses the development, production, and commercialization of tools and technologies critical for detecting cancer, including imaging tests (e.g., X-rays, CT scans, MRI), blood tests, biopsies, and molecular diagnostics such as genetic and tumor marker tests. This market is vital to the healthcare industry, as early and accurate diagnosis significantly improves patient outcomes by enabling timely treatment. The market is projected to experience robust growth from 2025 to 2030, driven by rising cancer incidence and technological advancements. However, challenges such as high costs and limited access in developing regions may hinder progress.

Market Drivers

The primary driver of the cancer diagnostics market is the escalating global incidence of cancer, which increases the demand for effective diagnostic tools. The growing burden of cancer, particularly breast cancer, underscores the need for early detection to enhance treatment success rates. Government support is another key factor, with initiatives like expedited regulatory approvals for innovative diagnostics boosting market growth. For instance, regulatory bodies are increasingly recognizing the potential of advanced diagnostic technologies, such as liquid biopsies, to improve early detection and patient outcomes. Additionally, heightened investment in research and development by industry players is fostering innovation in diagnostic solutions, further propelling the market.

Market Restraints

The cancer diagnostics market faces challenges, including the high cost of advanced diagnostic technologies, which can limit accessibility, particularly in low-resource settings. Additionally, disparities in healthcare infrastructure across regions hinder the widespread adoption of sophisticated diagnostics. Limited awareness and access to screening programs in developing countries also pose barriers, potentially delaying diagnoses and impacting market growth. Addressing these challenges through cost-effective solutions and expanded healthcare access will be critical for sustained market expansion.

Market Segmentation

By Diagnostic Procedures

The cancer diagnostics market is segmented into laboratory tests, imaging procedures, and biopsies. Laboratory tests, including blood, urine, and genetic tests, are expected to hold a significant market share due to their versatility and increasing use in early detection. Imaging procedures, such as CT scans and MRIs, remain essential for visualizing tumors, while biopsies provide definitive diagnoses. The laboratory test segment is anticipated to grow steadily, driven by advancements in molecular diagnostics and tumor marker tests.

By Cancer Type

Breast cancer diagnostics represent a substantial market segment, driven by the disease's high prevalence among women globally. The surge in investment in breast cancer diagnostic tools, including advanced imaging and molecular tests, is expected to fuel growth in this segment. Other cancer types, such as lung and colorectal, also contribute to market demand, with diagnostics tailored to specific genetic and biomarker profiles gaining traction.

By Geography

The global cancer diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East and Africa. Asia-Pacific leads in cancer incidence due to its large population, driving significant demand for diagnostics. North America and Europe follow, with advanced healthcare systems and high adoption of cutting-edge technologies. In the United States, factors such as rising alcohol and tobacco consumption, sedentary lifestyles, and genetic predispositions contribute to market growth, with increasing cancer cases necessitating enhanced diagnostic and screening efforts. Emerging regions like South America and the Middle East and Africa are expected to grow as healthcare infrastructure improves.

Key Industry Players

Major players in the cancer diagnostics market include bioMerieux SA, F. Hoffmann-La Roche Ltd, Sienna Cancer Diagnostics, and Insight Medical Genetics. These companies are heavily investing in research and development to advance diagnostic technologies, such as next-generation sequencing and liquid biopsies, to meet growing demand and improve diagnostic accuracy.

The cancer diagnostics market is set for significant growth from 2025 to 2030, driven by rising cancer incidence, government support, and technological innovations. Despite challenges like high costs and limited access, the market's outlook remains positive, particularly in high-incidence regions like Asia-Pacific and advanced markets like North America. Industry players must focus on affordability and accessibility to fully capitalize on the growing demand for early and accurate cancer diagnostics.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Global Critical Care Diagnostics Market Segmentation

By Diagnostic Procedure

• Laboratory Test
• Imaging Procedures
• Biopsy

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Skin Cancer
• Stomach Cancer
• Others

By End-User

• Hospitals
• Clinics
• Diagnostics Centers

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• South Korea
• Taiwan
• Indonesia
• Japan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER DIAGNOSTICS MARKET BY DIAGNOSTICS PROCEDURES

• 5.1. Introduction
• 5.2. Laboratory Test
• 5.3. Imaging Procedures
• 5.4. Bipsy

6. GLOBAL CANCER DIAGNOSTICS MARKET BY CANCER TYPE

• 6.1. Introduction
• 6.2. Lung cancer
• 6.3. Breast cancer
• 6.4. Colorectal Cancer
• 6.5. Skin Cancer
• 6.6. Stomach Cancer
• 6.7. Others

7. GLOBAL CANCER DIAGNOSTICS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Clinics
• 7.4. Diagnostics Centers

8. GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Diagnostic Procedures
  • 8.2.2. By Cancer Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Diagnostic Procedures
  • 8.3.2. By Cancer Type
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Diagnostic Procedures
  • 8.4.2. By Cancer Type
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Diagnostic Procedures
  • 8.5.2. By Cancer Type
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. By Diagnostic Procedures
  • 8.6.2. By Cancer Type
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. bioMerieux SA
• 10.2. Roche Diagnostics
• 10.3. MetaCell
• 10.4. Breath Diagnostics, Inc
• 10.5. Metabiomics
• 10.6. Castle Biosciences, Inc.
• 10.7. Exact Sciences Corporation
• 10.8. Thermo Fisher Scientific Inc.
• 10.9. Abbott Laboratories
• 10.10. GE Healthcare
• 10.11. Siemens Healthineers (Siemens AG)

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations